ELLEN GONCALVES DE OLIVEIRA

Mrs. ELLEN GONCALVES DE OLIVEIRA


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
EOELLEN GONCALVES DE OLIVEIRA
ELLEN GONCALVES DE OLIVEIRA
JCJoão Victor Rodrigues Pessoa Carvalho
João Victor Rodrigues Pessoa Carvalho
BRUNA BARBOSA FAGUNDES BOTELHOBRUNA BARBOSA FAGUNDES BOTELHO
BRUNA BARBOSA FAGUNDES BOTELHO
CFClécio Alonso da Costa Filho
Clécio Alonso da Costa Filho
LHLethicia Ribeiro Henriques
Lethicia Ribeiro Henriques
Rodrigo RodriguesRodrigo Rodrigues
Rodrigo Rodrigues
The global demand for industrial enzymes has been increasing in recent years, and the search for new sources of these biological products is intense, especially in microorganisms. Most known viruses have limited genetic machinery and, thus, have been overlooked by the enzyme industry for years. However, a peculiar group of viruses breaks this paradigm. Giant viruses of the phylum Nucleocytoviricota infect protists (i.e., algae and amoebae) and have complex genomes, reaching up to 2.7 Mb in length and encoding hundreds of genes. Different giant viruses have robust metabolic machinery, especially those in the Phycodnaviridae and Mimiviridae families. In this review, we present some peculiarities of giant viruses that infect protists and discuss why they should be seen as an outstanding source of new enzymes. We revisited the genomes of representatives of different groups of giant viruses and put together information about their enzymatic machinery, highlighting several genes to be explored in biotechnology involved in carbohydrate metabolism, DNA replication, and RNA processing, among others. Finally, we present additional evidence based on structural biology using chitinase as a model to reinforce the role of giant viruses as a source of novel enzymes for biotechnological application.

17 April 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
EOELLEN GONCALVES DE OLIVEIRA
ELLEN GONCALVES DE OLIVEIRA
JLJuliane Sousa Lanza
Juliane Sousa Lanza
SCSandrine Cojean
Sandrine Cojean
PMPaulo Otávio L. Moreira
Paulo Otávio L. Moreira
LTLuiza Guimarães Tunes
Luiza Guimarães Tunes
RMRubens Monte-Neto
Rubens Monte-Neto
Leishmaniasis chemotherapy faces significant challenges, including high costs, severe side effects, and the emergence of drug-resistant parasites, demanding global efforts to identify novel antileishmanial agents. Pentavalent antimony (SbV), the primary treatment for over 78 years, suffers from reduced efficacy and high toxicity, underscoring the urgent need for alternatives. We have synthesized metalloporphyrins with potent antileishmanial properties, including the SbV-porphyrin complex (SbVT4MPP). SbVT4MPP exhibited high potency against both Sb-sensitive and Sb-resistant Leishmania spp. with IC50 as low as 0.05 and 0.12 µM, respectively, for amastigotes and promastigotes; 170-fold more effective than SbV and with a 28-37-fold selectivity index, highlighting the importance of host cells on drug activity. Sterol profiling of L. infantum revealed that SbVT4MPP ablated ergosterol production while accumulating cholestane-based sterols (e.g., cholesta-5,7,22-trien-3β-ol). Additional sterols appeared exclusively under SbVT4MPP treatment, accompanied by upregulated erg6, encoding sterol-C-24 methyltransferase (SMT), a key enzyme in sterol biosynthesis. Overexpression of ERG6 reduced SbVT4MPP potency, increasing the IC50 by 2.5-fold, confirming ERG6's role in its mode of action. Disruption of ergosterol biosynthesis was indirectly confirmed through hypoosmotic shock assays, which indicated increased membrane fluidity in SbVT4MPP-treated Leishmania. In vivo studies revealed a 96 % reduction in parasite load, highlighting SbVT4MPP's efficacy in visceral leishmaniasis model. Since ERG6 is absent in mammals, it represents a selective and promising pharmacological target. Our findings position SbVT4MPP as a novel chemical entity with potent in vitro and in vivo antileishmanial efficacy, providing mechanistic insights and warranting further preclinical investigation as a promising drug candidate for leishmaniasis treatment.

15 February 2025 in Future Pharmacology
Verified
Journal Article
Open access
PDF file
FOFernanda Oliveira
Fernanda Oliveira
BRBeatriz Ribeiro
Beatriz Ribeiro
EOELLEN GONCALVES DE OLIVEIRA
ELLEN GONCALVES DE OLIVEIRA
MVMarina Mol Sena Andrade Verzola
Marina Mol Sena Andrade Verzola
TKThales Kronenberger
Thales Kronenberger
MSMateus Sá Magalhães Serafim
Mateus Sá Magalhães Serafim
Background/Objectives: Zika fever is a disease caused by the Zika virus (ZIKV). Symptomatic cases may be associated with neurological disorders in adults, as well as congenital Zika syndrome and other birth defects during pregnancy. In 2016, Zika fever was considered a public health problem by the World Health Organization (WHO), highlighting the need to develop new therapies against the disease. Currently, there is no antiviral or vaccine available to treat or prevent severe cases. Due to the lack of available therapeutics and few promising hit molecules, we computationally screened the well-described ZIKV protease (NS3pro) as a drug target to revisit the small-molecule database Brazilian Compound Library (BraCoLi) and select potential inhibitors. Methods: We employed a consensus docking screening of a library of 1176 compounds using GOLD and DockThor. We selected 28 hits based on predicted binding affinity, and only the remnants of three compounds were available in the library at the time of this study for experimental validation. The hits were evaluated for their cytotoxic (CC50) and effective concentrations (EC50) for their potential antiviral activity in Vero cells. Results: The three hit compounds presented modest CC50 values of 89.15 ± 3.72, >100, and 29.67 ± 1.01 μM, with the latter, a carbohydrate derivative, having an EC50 value of >12.5 μM (~40% inhibition) against ZIKV PE243. Additionally, the essentially non-toxic compound, an arylfuran derivative, also inhibited the ZIKV NS3pro with an IC50 value of 17 μM but presented evidence of acting through a promiscuous mechanism for enzyme inhibition. Conclusion: This study highlights the relevance of revisiting existing small-molecule assets to identify novel therapeutic starting points against ZIKV, aiming for potential lead candidates in the future.

4 June 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
PFPhilipp Flury
Philipp Flury
JVJyoti Vishwakarma
Jyoti Vishwakarma
KSKatharina Sylvester
Katharina Sylvester
NHNobuyo Higashi-Kuwata
Nobuyo Higashi-Kuwata
ADAgnieszka Dabrowska
Agnieszka Dabrowska
Thanigaimalai PillaiyarThanigaimalai Pillaiyar
Thanigaimalai Pillaiyar
The main protease (Mpro) of SARS-CoV-2 plays a crucial role in the replication and pathogenesis of the virus. The relatively high conservation within the Coronaviridae family makes it an attractive therapeutic target for developing broad-spectrum agents to prevent and control SARS-CoV-2 and potentially future coronavirus-associated diseases. This study describes the design, synthesis, and structure-activity relationships of azapeptide-based SARS-CoV-2 Mpro inhibitors, leading to several compounds with low nanomolar IC50 values. Examples include 14r (IC50 = 13.3 nM), 14s (IC50 = 30.6 nM), 20a (TPG-25-1, IC50 = 34.7 nM), 20g (IC50 = 30.4 nM), and 20h (IC50 = 31.3 nM). Some compounds inhibit MERS-CoV and SARS-CoV-1 Mpro but not the human protease cathepsin L. Several inhibitors, particularly 20a and 20f, exhibit antiviral activity with potencies comparable to nirmatrelvir and were highly potent against the E166V-carrying SARS-CoV-2 variant (SARS-CoV-2E166V). An Mpro co-crystal structure with 20a shows a covalent adduct with the catalytic Cys145. Overall, these new inhibitors are promising chemical tools that may contribute to the identification of future pan-anti-coronaviral drugs.